Psoriasis
Conditions
Brief summary
The aim of this study is to determine whether oral Chinese herbal medicine in combination secukinumab is effective and safe in the treatment of severe psoriasis.
Detailed description
The aim of this study is to determine whether oral Chinese herbal medicine in combination with secukinumab is effective and safe in the treatment of severe psoriasis. Eligible participants will be treated with oral Chinese herbal medicine and secukinumab concurrently. No controlled group will be set up in this trial. The primary outcome is time to relapse. Secondary outcomes include Psoriasis Area and Severity Index (PASI) 75/90, PASI score reduction rate, physician's global assessment (PGA) score, body surface area (BSA) score, visual analogue scale (VAS) score, dermatology life quality index (QLQI) and Skindex 16.
Interventions
DRUGGu Ben Hua Yu Fang decoction (Chinese herbal medicine)
Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
DRUGSecukinumab Auto-Injector [Cosentyx]
Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
Sponsors
Guangdong Provincial Hospital of Traditional Chinese Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Psoriasis Area and Severity Index (PASI) score≥10 2. Meet the requirement of using secukinumab; without the history of inflammatory bowel disease (IBD) 3. Written/signed informed consent
Exclusion criteria
1\. Unsuitable for the treatment of secukinumab
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Median time to relapse | Through study completion, an average of 1 year | Median time to relapse is a time interval. The time interval will be recorded between the end of treatment and the occurrence of relapse. Relapse was defined as loss of \> 50% of maximum Psoriasis Area and Severity Index (PASI) improvement compared with pretreatment baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PASI-75 | 16 weeks after treatment | The proportion of patients who achieve at least 75% improvement in PASI score from baseline. |
| PASI-90 | 16 weeks after treatment | The proportion of patients who achieve at least 90% improvement in PASI score from baseline. |
| Physician's global assessment (PGA) score | Assessment will be conducted on week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year. | Physician's global assessment for the condition |
| Pruritus Scores on the Visual Analogue Scale | Assessment will be conducted on week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year. | Pruritus will be assessed using the Visual Analogue Scales; The Scale scores ranged from 0-10; the higher the scores are, the more itching the patients suffer. |
| Psoriasis Area and Severity Index (PASI) score | Assessment will be conducted at week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year | The improvement in Psoriasis Area and Severity Index (PASI) score from baseline after treatment; the scale scores ranged from 0-72. The higher the scores are, the more severe the patients suffer |
| Dermatology Life Quality Index (DLQI) | Assessment will be conducted on week 0, 16 and the end of study completion (once relapse occurs, an average of 1 year). | Questionnaire for disease-specific quality of life |
| Skindex16 | Assessment will be conducted on week 0, 16 and the end of study completion (once relapse occurs, an average of 1 year). | Questionnaire for disease-specific quality of life |
| patients' attitudes, expectation and experience | Interview will be conducted on week 0, 16 and the end of study completion (once relapse occurs, an average of 1 year). | Semi-structured individual interview will be conducted to explore patients' understanding and expectation for the combination therapy used in this study. Patients' experience of using the combination therapy will be recorded as well. |
| BSA | Assessment will be conducted on week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year. | the Body Surface Area |
Countries
China
Contacts
Primary ContactChuanjian Lu, PhD
Backup ContactJingjie Yu, PhD
Outcome results
None listed